Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:
Whether you’re shedding pounds with the help of effective new medicines, slimming down after weight loss surgery or cutting calories and adding exercise, there will come a day when the numbers on the scale stop going down, and you hit the dreaded weight loss plateau.
In a recent study, Kevin Hall, a researcher at the National Institutes of Health who specializes in measuring metabolism and weight change, looked at when weight loss typically stops depending on the method people were using todrop pounds. He broke down the plateau into mathematical models using data from high-quality clinical trials of different ways to lose weight to understand why people stop losing when they do. The study published Monday in the journal Obesity.
In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential vaccines would require multiple doses or the addition of adjuvants, which enhance the immune response. With hopes of making one dose of an inactivated H7N9 vaccine fully protective, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) successfully tested a prime-boost concept in a small clinical trial. The “primer” pandemic influenza vaccine—made from live but weakened virus—introduces the immune system to H7N9 influenza virus, and subsequent vaccination with the “booster” inactivated virus vaccine recalls a more robust immune response.
H7N9 influenza emerged in spring 2013 in China, primarily affecting people who have close contact with poultry. Through Nov. 13, 2015, the World Health Organization has reported 681 confirmed cases with at least 275 deaths. H7N9 influenza has not been found in the United States.
Riboflavin (vitamin B2) helps children overcome the devastating effects of a hereditary brain disorder by helping one protein fill in for a disabled protein, according to a study by researchers at the National Institutes of Health (NIH) and other institutions. The findings offer the prospect that researchers may be able to improve the treatment for infantile leukoencephalopathy, a rare brain disorder resulting in blindness, debilitation, and early death.
The study appears in Cell Metabolism and was conducted by Nunziata Maio, Ph.D, and Tracey Rouault, Ph.D., of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development and colleagues in Italy and the United Kingdom.
People and other mammals rely on taste to guide food choices. For example, we’re attracted to sweet foods, which are usually rich in energy. A bitter taste, on the other hand, may be a warning sign of potentially harmful chemicals.
Over the past 17 years, the laboratories of Dr. Nicholas Ryba of NIH’s National Institute of Dental and Craniofacial Research (NIDCR) and Dr. Charles Zuker from the Howard Hughes Medical Institute at Columbia University Medical Center have identified the receptor cells in the tongue that detect sweet, sour, bitter, umami (savory), and salt tastes. Information from these cells is relayed to the primary gustatory cortex, or taste cortex, in the brain.
A new, open-source software that can help track the embryonic development and movement of neuronal cells throughout the body of the worm, is now available to scientists. The software is described in a paper published in the open access journal, eLife on December 3rd by researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the Center for Information Technology (CIT); along with Memorial Sloan-Kettering Institute, New York City; Yale University, New Haven, Connecticut; Zhejiang University, China; and the University of Connecticut Health Center, Farmington. NIBIB is part of the National Institutes of Health.
As far as biologists have come in understanding the brain, much remains to be revealed. One significant challenge is determining the formation of complex neuronal structures made up of billions of cells in the human brain. As with many biological challenges, researchers are first examining this question in simpler organisms, such as worms.
Image A shows the twisted up worm embryo inside the egg with the fluorescently labeled cells. The second image shows how the computer program identifies each of the marked cells, and image C shows the untwisted worm.
Gene therapy can safely rebuild the immune systems of older children and young adults with X-linked severe combined immunodeficiency (SCID-X1), a rare inherited disorder that primarily affects males, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have found. NIAID’s Suk See De Ravin, M.D., Ph.D., is scheduled to describe the findings at the 57th American Society of Hematology Annual Meeting in Orlando, Florida.
SCID-X1 is caused by mutations in the IL2RG gene that prevent infection-fighting immune cells from developing and functioning normally, leaving affected infants highly susceptible to life-threatening infections. Transplantation of blood-forming stem cells, ideally from a genetically matched sibling donor, is a lifesaving treatment for infants with SCID-X1. Those without a matched sibling often receive stem cells from a parent, which only partially restores immunity. Such patients require lifelong treatment and may continue to experience complex medical problems, including chronic infections.
For many years, clinicians debated the best time to start antiretroviral therapy (ART) for HIV infection, with some worrying that the risks of treatment in terms of drug toxicities could outweigh the benefits of controlling the virus. In a new commentary, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, argue that the results of three large clinical trials definitively prove that the benefits of starting ART early in infection outweigh any theoretical risk. Together, the findings from the NIH-funded SMART study reported in 2006, HPTN 052 study in 2011 and START study this year conclusively demonstrate that starting ART promptly after HIV diagnosis protects the health of the infected individual while preventing HIV transmission to uninfected sexual partners, the authors write.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases Carl Dieffenbach, Ph.D., Director, Division of AIDS, NIAID Francis S. Collins, M.D., Ph.D., NIH Director
When the first cases of what would become known as AIDS were reported in 1981, scientists and physicians did not know the cause and had no therapies to treat those who were infected. Times have changed and today physicians can offer their patients highly effective medicines that work as both treatment and prevention. We can now speak credibly about having within our sights the end to the HIV/AIDS pandemic, when new HIV infections and deaths due to AIDS are rare.
Ending the HIV/AIDS pandemic as we know it will require using antiretroviral therapy (ART) to treat all infected people upon diagnosis, facilitating the implementation of an array of prevention tools including pre-exposure prophylaxis, and eliminating mother-to-child HIV transmission. While recent scientific advances demonstrate these objectives are all possible, we must encourage universal HIV testing so that people know their status and are linked to care if infected and linked to a prevention program if at risk of infection. Approximately 50,000 people in the United States are newly infected with HIV each year, and about 1 in 8 of the 1.2 million who currently are infected do not know their status. Tragically, nearly a third of all new HIV infections in this country are transmitted by people who are unaware of their infection; another 60 percent of infections arise from people who are diagnosed but not in care.
In a Federal Register notice on Nov. 25, 2015, the U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), led the development of the criteria, which provide the framework for clinical studies on transplantation of HIV-infected organs to begin in the United States as early as 2016.
The HIV Organ Policy Equity (HOPE) Act, signed into law on Nov. 21, 2013, allows scientists to carry out research into organ donations from one person with HIV infection to another and mandates development of safeguards and criteria for the conduct of such research. Prior to passage of this law, transplantation of organs from people with HIV infection was illegal in the United States.
In the United States, and throughout the world, men drink more alcohol than women. But a recent analysis by scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, indicates that longstanding differences between men and women in alcohol consumption and alcohol-related harms might be narrowing in the United States.
Researchers led by Aaron White, Ph.D., NIAAA’s senior scientific advisor to the director, examined data from yearly national surveys conducted between 2002 and 2012.
A newly discovered link between order in the activity of neurons in the brain and excitability—how likely it is that individual neurons will “fire”—may provide a means for monitoring treatment of conditions like epilepsy that would be less invasive and thus more versatile than current methods. This new approach, developed by NIMH scientists, has implications beyond conditions like epilepsy; the findings support an emerging picture of how the brain balances flexibility and order during wakefulness and sleep.
